Results 201 to 210 of about 3,377,180 (268)

Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia. [PDF]

MedComm (2020)
Musso G, Pinach S, Mella A, De Michieli F, Calabrese A, Trifiro D, Petrangolini G, Cassader M, Mariano F, Gambino R.   +9 more
europepmc   +1 more source

The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Obstructive Sleep Apnea and Obesity. [PDF]

Curr Pulmonol Rep
Ellberg CC, Schwartz H, Witt A, McCowen KC, Fuentes AL, Malhotra A.   +5 more
europepmc   +1 more source

Dual Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Tirzepatide Use. [PDF]

Cureus
Humaida S, Manzalji K, Seyam N, Al-Masalmani L.   +3 more
europepmc   +1 more source

Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial. [PDF]

Diabetes Obes Metab
Chakravarthy MV, Elliott MA, Acosta L, Sonnenberg GE, Bialonczyk D, Wu J, Argüelles-Tello FA, Garcia-Reza R, González-González JG, Hansen SK, Frias JP.   +10 more
europepmc   +1 more source

Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes? [PDF]

J Endocrinol
Lafferty RA, Flatt PR, Gault VA, Irwin N.   +3 more
europepmc   +1 more source

A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide Receptors. [PDF]

J Clin Transl Hepatol
Jiang J, Shi M, Wu S, Cao M.
europepmc   +1 more source

Correction to: "Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease".

Endocr Rev
europepmc   +1 more source

Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists. [PDF]

Cochrane Database Syst Rev
Grenet G, Gougeon A, Salzwedel DM, Jauca CD, Wright JM.   +4 more
europepmc   +1 more source

Glucose-dependent insulinotropic polypeptide receptor systems in the hypothalamus and the brainstem regulate feeding and weight through distinct pathways. [PDF]

J Diabetes Investig
Yada T.
europepmc   +1 more source

The effect of glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis, differentiation, and plasticity (Neuro-GDP): potential mechanistically informed therapeutics in the treatment and prevention of mental disorders. [PDF]

CNS Spectr
McIntyre RS, Rasgon N, Goldberg J, Wong S, Le GH, Mansur RB, Rosenblat JD, Teopiz KM, Stahl SM.   +8 more
europepmc   +1 more source